Cannabis investors gathered in Toronto this week for the Benzinga Cannabis Capital Conference. They heard from leaders of the industry on what the next steps for the entire sector look like.

The two day event kicked off on Wednesday (April 17) with in-depth panel discussions on smart cannabis investments and the potential of expanding a Canadian business into the US.

Following a keynote speech from KushCo Holdings (OTCQB:KSHB) President Jason Vegotsky, investors heard a panel of experts discuss how Canadian firms may position for entry to the US and other international expansion plans.

Alfred Avanessy, managing director of Cormark Securities, said the Canadian experience has involved a “rush to scale,” meaning a lot of merger and acquisition activity.

“If you look at the Canadian experience, the companies that end up becoming the leaders and the ones that attracted what we now talk about as the strategic dollars … were the ones that moved the fastest, quickest, and there was a lot of acquisition to achieve that growth rate.”

One clear sign of this volatile acquisition path is a new deal brokered between Canadian producer Canopy Growth (NYSE:CGC,TSX:WEED) and multi-state operator (MSO) Acreage Holdings (CSE:ACRG.U,OTCQX:ACRGF).

During his keynote, Steve White, CEO of Harvest Health & Recreation (CSE:HARV,OTCQX:HRVSF), credited the management team of Canopy for its ability to stay ahead of competitors.

The event dedicated some time to the evolving Canadian market, with a panel hosting representatives from a group of Canadian firms.

The panelists were asked about concerns regarding supply issues in the country, and the expectations on oversupply for the northern market.

Ray Gracewood, chief commercial officer at OrganiGram Holdings (TSXV:OGI,OTCQX:OGRMF), said exploration outside the Canadian space can allow for breathing room on the supply front.

“I think at the end of the day, right now it’s about developing our international business and understanding beyond Canadian borders what kind of opportunities present themselves,” he said.

He added his company has put an emphasis on making sure to make the “right relationships” when it comes to the partners available for international expansions.

Later in the day, Tim Seymour, chief investment officer of Seymour Asset Management and frequent contributor to CNBC’s “Fast Money,” moderated a discussion on how to make the right investment in the cannabis space.

His first question to the panelists related to whether there’s more value to be found in the public or private markets.

Matt Hawkins, managing principal at Cresco Capital Partners, said private investments are the most attractive for his firm.

Narbe Alexandrian, president of Canopy Rivers (TSXV:RIV,OTC Pink:CNPOF), agreed with Hawkins and highlighted the talent rising from the cannabis private sector. “I do think there’s a lot of value in private companies right now, in the sense that there’s a lot of hidden talent,” he said.

Alexandrian added that he has noticed a variety of people switching from established tech firms for marijuana opportunities.

“Folks [are] coming out of the CPG realm, traditional family brands trying to create brands in the cannabis space that their parent companies wouldn’t touch, so you’re seeing a lot of opportunity on the private side, which I call the disruptors,” the executive for the investment firm said.

The panel also discussed one of the most difficult elements of evaluation in the cannabis space: experience and success with management teams.

Jon Trauben, partner with venture capital fund Altitude Investment Management, said that evaluating the team at a company can be more complicated than valuations.

“It’s great when we have experienced people coming from an outside industry [and] bringing their skillset here,” Trauben said.

When it comes to valuations, Tahira Rehmatullah, managing director at venture capital fund Hypur Ventures, said in this space it is usually not a straightforward affair.

“Valuations are definitely an art, not a science, so those are always moving targets. You’ll find somebody value one company at 15 times revenue, and then another one will say ‘no, I’ll give you one time, that’s what I think the value of the company is,’ and it’s that broad of a range.”

With the increased attention on MSOs, a panel of executives from public firms such as iAnthus Capital Holdings (CSE:IAN,OTCQX:ITHUF), Trulieve Cannabis (CSE:TRUL,OTC Pink:TCNNF) and MedMen Enterprises (CSE:MMEN,OTCQX:MMNFF) discussed the landscape for this market.

Kim Rivers, CEO of Trulieve, said she expects to see more merger and acquisition activity as the competition between MSOs continues its ramp up.

Near the end of the first day, investors took in a conversation between Richard Carleton, CEO of the Canadian Securities Exchange, and Charlie Bachtell, CEO of MSO Cresco Labs (CSE:CL,OTCQX:CRLBF).

The cannabis executive was asked for his perception on the differences in valuation between Canadian companies and the popular MSOs, which trade at a significant discount from their Canadian counterparts.

“I think you’re seeing these closing of the gaps, you’re seeing higher valuations, lower market caps on some of the fellow peers on the US side. I think the obvious advantage right now is that those Canadian operators have access to the US capital markets,” Bachtell said.

“They have access to the institutional investors that would invest in the US capital markets and they have access to the US retail investor too,” he said referencing the ability of Canadian firms to reach senior exchanges in New York so long as these companies don’t operate any illegal cannabis assets.

However, Bachtell added that, once legislation changes take place in the US, that will change.

“As soon as those institutions and the US retail investor has the ability to readily and easily invest in US operators, I think you’re going to see a transition there,” he said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Acreage Holdings is a client of the Investing News Network. This article is not paid-for content.

The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less